Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

被引:0
|
作者
Jens Ingwersen
Orhan Aktas
Hans-Peter Hartung
机构
[1] Heinrich Heine University Düsseldorf,Department of Neurology, Medical Faculty, University Hospital
来源
Neurotherapeutics | 2016年 / 13卷
关键词
Relapsing-remitting multiple sclerosis; Disease-modifying therapy; Treatment decisions; Treatment algorithm;
D O I
暂无
中图分类号
学科分类号
摘要
Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.
引用
收藏
页码:47 / 57
页数:10
相关论文
共 50 条
  • [1] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Ingwersen, Jens
    Aktas, Orhan
    Hartung, Hans-Peter
    [J]. NEUROTHERAPEUTICS, 2016, 13 (01) : 47 - 57
  • [2] Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
    Gasperini, Claudio
    Ruggieri, Serena
    Mancinelli, Chiara Rosa
    Pozzilli, Carlo
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 73 - 85
  • [3] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [4] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [5] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [6] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [7] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    [J]. NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [8] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [9] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    [J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19
  • [10] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110